|
|
Our experts have been researching and providing insight to pharmaceutical and biotechnology professionals since 1992.
See below for a listing of executive briefs published by our firm.
|
|
Four Things Marketers Need to do Before an NDA is Submitted, September 2012.
Traditionally, the period between completion of Phase II trials and submission of an NDA has been a relatively quiet time for the marketing team for a new brand. It wasn't until 18–24 months before launch that marketing planning really began in earnest. In today’s market, teams jeopardize the success of their brands if they wait until NDAs are submitted to begin planning.
|
The Institutional Market, June 2012.
There was a time when manufacturers could rely on institutional customers for their predictability, even when other markets were experiencing major shakeups. But those days are over. Today, hospitals, health systems, and group purchasing organizations (GPOs) aren't the customers they used to be, thanks to a convergence of trends.
|
What Matters Most to Hospitals and Health Systems, April 2012.
Within the institutional channel, quality counts—particularly when it comes to relationships. This is especially true now for institutional channel customers, as the key people in the decision-making process are changing from the influence of the traditional physician to other stakeholders such as C-Suite, pharmacy stakeholders (pharmacy directors, clinical pharmacists, etc.) and medical stakeholders (medical directors, directors of nursing, etc.).
|
Payer Access Decisions in CNS Drugs, April 2012.
Four categories of drugs that treat central nervous system (CNS) conditions—antiepileptics, antidepressants, antipsychotics, and neuropathic pain agents—share similar market dynamics. In these categories, several mature agents as well as generics dominate the space. In turn, payers seek to capitalize on opportunities to limit brand use and encourage use of low-cost generics.
|
Oncology Pathway Development and Evolution, April 2012.
In today's oncology market, a new force is emerging that promises to have an even greater impact in the future: the pathway developer. In fact, treatment pathways are already having an impact on oncologists' prescribing habits. As part of its Oncology Performance Edge research series, Health Strategies Group released a new report in March 2012 that details the emergence of pathway developers—and the implications for oncology companies.
|
Why SPMs Cant Be Ignored, January 2012.
During the past five years, specialty pharmacy managers have grown dramatically. Accounting for mergers, acquisitions, and company growth and dissolutions, half of the leading SPM companies have changed 50%, and revenues have grown 7 to 10-fold from 2003 to 2009. This alone strongly predicts substantive change in network vendor relationships for payers and companies over the next three to five years. In addition, niche SPMs are emerging, capitalizing on their strength of geographic coverage, physician relationships, disease management expertise, or technological expertise. We estimate there are roughly 200 or more SPMs operating with significant revenue focus throughout the United States.
|
|
|
